[1] |
Dupin N. Update on oncogenesis and therapy for Kaposi sarcoma[J]. Curr Opin Oncol, 2020,32(2):122⁃128. doi:10.1097/cco. 0000000000000601.
|
[2] |
Odyakmaz Demirsoy E, Bayramgürler D, Çağlayan Ç, et al. Imiquimod 5% cream versus cryotherapy in classic Kaposi sarcoma[J]. J Cutan Med Surg, 2019,23(5):488⁃495. doi: 10. 1177/1203475419847954.
|
[3] |
Meseguer⁃Yebra C, Cardeñoso⁃Álvarez ME, Bordel⁃Gómez MT, et al. Successful treatment of classic Kaposi sarcoma with topical timolol: report of two cases[J]. Br J Dermatol, 2015,173(3):860⁃862. doi:10.1111/bjd.13746.
|
[4] |
Alcántara⁃Reifs CM, Salido⁃Vallejo R, Garnacho⁃Saucedo GM, et al. Classic Kaposi′s sarcoma treated with topical 0.5% timolol gel[J]. Dermatol Ther, 2016,29(5):309⁃311. doi:10.1111/dth. 12381.
|
[5] |
Sainz⁃Gaspar L, Suárez⁃Peñaranda JM , Pousa⁃Martínez M, et al. Topical timolol for treatment of penile Kaposi sarcoma in HIV⁃negative patient[J]. Dermatol Ther, 2017,30(5). doi: 10.1111/dth.12519.
|
[6] |
Abdelmaksoud A, Filoni A, Giudice G, et al. Classic and HIV⁃related Kaposi sarcoma treated with 0.1% topical timolol gel[J]. J Am Acad Dermatol, 2017,76(1):153⁃155. doi: 10.1016/j.jaad. 2016.08.041.
|
[7] |
Abdelmaksoud A, Filoni A, Giudice G, et al, Topical timolol for Kaposi sarcoma: an innovation[J]. Australas J Dermatol, 2018,59(4):340⁃341. doi:10.1111/ajd.12817.
|
[8] |
Delinikolas P, Patatoukas G, Kouloulias V, et al. A novel Hemi⁃Body Irradiation technique using electron beams (HBIe(⁃))[J]. 2018,46:16⁃24.
|
[9] |
Platoni K, Diamantopoulos S, Dilvoi M, et al. First application of hemi⁃body electron beam irradiation for Kaposi sarcoma at the lower extremities[J]. J BUON, 2018,23(1):268⁃272.
|
[10] |
Kim SW, Kim C, Cho MS, et al. Clinical implementation of a wide⁃field electron arc technique with a scatterer for widespread Kaposi′s sarcoma in the distal extremities[J]. Sci Rep, 2020,10(1):9693. doi: 10.1038/s41598⁃020⁃66846⁃5.
|
[11] |
Tourlaki A, Germiniasi F, Rossi LC, et al. Paclitaxel as first⁃ or second⁃line treatment for HIV⁃negative Kaposi′s sarcoma: a retrospective study of 58 patients[J]. J Dermatolog Treat, 2020,31(2):183⁃185. doi: 10.1080/09546634.2019.1590520.
|
[12] |
Lebbe C, Garbe C, Stratigos AJ, et al. Diagnosis and treatment of Kaposi′s sarcoma: European consensus⁃based interdisciplinary guideline (EDF/EADO/EORTC)[J]. Eur J Cancer, 2019,114:117⁃127. doi: 10.1016/j.ejca.2018.12.036.
|
[13] |
Du Q, Jiang G, Li S, et al. Docetaxel increases the risk of severe infections in the treatment of non⁃small cell lung cancer: a meta⁃analysis[J]. Oncoscience, 2018,5(7⁃8):220⁃238. doi: 10.18632/oncoscience.444.
|
[14] |
Hosokawa Y, Kato J, Hida T, et al. Docetaxel therapy for classic Kaposi′s sarcoma[J]. Asia Pac J Clin Oncol, 2019,15(3):181⁃182. doi: 10.1111/ajco.13139.
|
[15] |
Park MK, Cho H, Roh SW, et al. Cell type⁃specific interferon⁃γ⁃mediated antagonism of KSHV lytic replication[J]. Sci Rep, 2019,9(1):2372. doi: 10.1038/s41598⁃019⁃38870⁃7.
|
[16] |
Springgay LK, Fitzpatrick K, Park B, et al. Rhesus macaque rhadinovirus encodes a viral interferon regulatory factor to disrupt promyelocytic leukemia nuclear bodies and antagonize type I interferon signaling[J]. J Virol, 2019,93(6):e02147⁃18. doi: 10.1128/JVI.02147⁃18.
|
[17] |
Harris B, Walsh JL, Neciunaite R, et al. Ring a ring o′roses, a patient with Kaposi′s? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy[J]. Clin Exp Dermatol, 2018,43(2):234⁃236. doi: 10.1111/ced.13302.
|
[18] |
Shaik F, Uldrick TS, Esterhuizen T, et al. Health⁃related quality of life in patients treated with antiretroviral therapy only versus chemotherapy and antiretroviral therapy for HIV⁃associated Kaposi sarcoma: a randomized control trial[J]. J Glob Oncol, 2018,4:1⁃9. doi: 10.1200/JGO.18.00105.
|
[19] |
Busakhala NW, Waako PJ, Strother MR, et al. Randomized phase IIA trial of gemcitabine compared with bleomycin plus vincristine for treatment of Kaposi′s sarcoma in patients on combination antiretroviral therapy in Western Kenya[J]. J Glob Oncol, 2018,4:1⁃9. doi: 10.1200/JGO.17.00077.
|
[20] |
Busakhala N, Kigen G, Waako P, et al. Three year survival among patients with aids⁃related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya[J]. Infect Agent Cancer, 2019,14:24. doi: 10.1186/s13027⁃019⁃0242⁃9.
|
[21] |
Krown SE, Moser CB, MacPhail P, et al. Treatment of advanced AIDS⁃associated Kaposi sarcoma in resource⁃limited settings: a three⁃arm, open⁃label, randomised, non⁃inferiority trial[J]. Lancet, 2020,395(10231):1195⁃1207. doi: 10.1016/S0140⁃6736(19)33222⁃2.
|
[22] |
Reid EG, Suazo A, Lensing SY, et al. Pilot trial AMC⁃063: safety and efficacy of bortezomib in AIDS⁃associated Kaposi sarcoma[J]. Clin Cancer Res, 2020,26(3):558⁃565. doi: 10.1158/ 1078⁃0432.CCR⁃19⁃1044.
|
[23] |
Genovese G, Venegoni L, Fanoni D, et al. PD⁃L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi′s sarcoma[J]. J Eur Acad Dermatol Venereol, 2019,33(7):e269⁃269e271. doi: 10.1111/jdv. 15543.
|
[24] |
Galanina N, Goodman AM, Cohen PR, et al. Successful treatment of HIV⁃associated Kaposi sarcoma with immune checkpoint blockade[J]. Cancer Immunol Res, 2018,6(10):1129⁃1135. doi: 10.1158/2326⁃6066.CIR⁃18⁃0121.
|
[25] |
Uldrick TS, Gonçalves PH, Abdul⁃Hay M, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer⁃A phase 1 study[J]. JAMA Oncol, 2019,5(9):1332⁃1339. doi: 10.1001/jamaoncol.2019.2244.
|
[26] |
Chang XB, Zhu YX, Shi CX, et al. Mechanism of immuno⁃modulatory drugs′ action in the treatment of multiple myeloma[J]. Acta Biochim Biophys Sin (Shanghai), 2014,46(3):240⁃253. doi: 10.1093/abbs/gmt142.
|
[27] |
Pourcher V, Desnoyer A, Assoumou L, et al. Phase II trial of lenalidomide in HIV⁃infected patients with previously treated Kaposi′s sarcoma: results of the ANRS 154 lenakap trial[J]. AIDS Res Hum Retroviruses, 2017,33(1):1⁃10. doi: 10.1089/AID.2016.0069.
|
[28] |
Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for symptomatic Kaposi′s sarcoma in people with and without HIV infection: a phase I/II study[J]. J Clin Oncol, 2016,34(34):4125⁃4131. doi: 10.1200/JCO.2016.69.3812.
|
[29] |
El⁃Mallawany NK, Villiera J, Kamiyango W, et al. Endemic Kaposi sarcoma in HIV⁃negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV⁃related disease[J]. Infect Agent Cancer, 2018,13:33. doi: 10.1186/s13027⁃018⁃0207⁃4.
|
[30] |
Delyon J, Bizot A, Battistella M, et al. PD⁃1 blockade with nivolumab in endemic Kaposi sarcoma[J]. Ann Oncol, 2018,29(4):1067⁃1069. doi: 10.1093/annonc/mdy006.
|
[31] |
Delyon J, Rabate C, Euvrard S, et al. Management of Kaposi sarcoma after solid organ transplantation: a European retrospective study[J]. J Am Acad Dermatol, 2019,81(2):448⁃455. doi: 10.1016/j.jaad.2019.03.028.
|
[32] |
Yamashiro A, Awazawa R, Ohira A, et al. Successful treatment of iatrogenic Kaposi′s sarcoma with low⁃dose docetaxel therapy[J]. J Dermatol, 2018,45(4):e96⁃96e97. doi: 10.1111/1346⁃8138. 14135.
|